Cyanokit

Quick links to important sections

Cyanokit

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cyanokit

Quick Facts

Property Description
Active Ingredient Hydroxocobalamin
Form Sterile powder for solution for infusion
Pharmacological Class Cyanide Antidote, Detoxifying Agent
Common Use Emergency treatment of cyanide poisoning
Origin Derived (Semisynthetic Cobalamin analog)

What is Cyanokit and Its Pharmacological Classification?

Cyanokit is a highly specialized, prescription-only medication classified as a Cyanide Antidote and Detoxifying Agent. Its primary purpose is to provide immediate intervention to rapidly counteract the acute effects of known or suspected cyanide poisoning. Its use is clinically recognized as a first-line treatment in numerous toxicology and emergency protocols. This medication falls under the Cobalamin class of compounds and is designated for rapid administration in critical situations, such as accidental or deliberate exposure to smoke from building fires.

Composition and Physical Form of Hydroxocobalamin

The active ingredient in Cyanokit is Hydroxocobalamin, which is structurally related to Vitamin B12a (Aquocobalamin). This single-ingredient product is supplied in a distinct kit format containing a sterile powder for solution for infusion. The powdered form ensures the stability necessary for a long shelf-life, which is crucial for emergency medications.

The kit requires reconstitution with a suitable diluent immediately prior to use to form a concentrated aqueous solution necessary for intravenous (IV) administration. The use of this specific chemical precursor, a derivative of the B-vitamin family, is fundamental to the drug's effectiveness.

How Does Cyanokit Neutralize the Toxin?

Cyanokit neutralizes the toxin through a principle known as high-affinity binding, which enables the Hydroxocobalamin to act as a chemical trap for the cyanide ion. Once administered, it rapidly captures the toxic cyanide molecules through cyanide ion sequestering. This action combines the two substances to form the stable, non-toxic compound cyanocobalamin, which is then safely cleared from the body. This chemical conversion is vital for reversing the impact of cyanide on the patient's ability to produce cellular energy.

What side effects are possible with Cyanokit?

Possible Side Effects and Safety Information

The safety profile of Hydroxocobalamin is documented by regulatory bodies, classifying adverse reactions by their physiological impact and frequency. The most distinguishing and Very Common (ge 1/10) effects are related to the drug's deep red color, including Chromaturia (red coloration of the urine) and reddish-brown discoloration of the skin and mucosa. These color changes are expected and may persist for up to 15 days.

Cardiovascular effects include a transient increase in blood pressure (hypertension), which is also classified as Very Common, typically resolving within a few hours. Common reactions (ge 1/100 to < 1/10) include various rashes (sometimes delayed in onset and prolonged in duration), headache, nausea, and vomiting. Infusion site reactions and hypersensitivity events are also documented in this category.

Serious adverse reactions officially listed in regulatory labels include anaphylactic reactions and the potential for Acute Renal Failure, which requires monitoring of renal function for up to seven days following administration. The drug’s intense color also presents a significant safety limitation: it is known to cause interference with clinical laboratory tests (colorimetric assays) for creatinine, hemoglobin, and bilirubin, potentially leading to inaccurate readings for approximately 48 hours and longer, depending on the persistence of chromaturia.

Specific considerations apply to patient populations, such as the need for careful renal function monitoring in patients with renal impairment. The safety profile is consistently structured in official documents to ensure a clear understanding of both expected and serious adverse reactions.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory literature indicates that no specific antidote is known for Hydroxocobalamin overexposure, and no standard toxicity syndrome is defined. Management for excessive exposure is limited to symptomatic and supportive treatment.

Documented High-Dose Manifestations

High therapeutic doses of the drug are associated with several officially documented physiological consequences and serious outcomes:

System Affected Manifestation (As Listed in Label)
Cardiovascular Substantial, transient hypertension and increased heart rate.
Renal System Potential for acute renal failure with acute tubular necrosis.
Diagnostics Interference with colorimetric laboratory assays and potential shutdown of hemodialysis machines due to erroneous blood leak detection.

When to Seek Immediate Medical Help

Given the risk of serious outcomes like acute renal injury, immediate medical attention must be sought for any suspected overdose. The FDA Prescribing Information advises contacting a Poison Control Center (e.g., 1-800-222-1222) for expert advice. Following administration, renal function must be monitored for up to seven days.

Therapeutic Uses of Cyanokit

What Cyanokit Treats: Main Uses and Benefits

Cyanokit (Hydroxocobalamin) is an emergency antidote used for the management of known or suspected acute systemic cyanide poisoning in all age groups. The medicine is applied in clinical settings that involve acute or unstable symptom patterns to help counteract the poison's effects, which are commonly encountered by victims of smoke inhalation from closed-space fires or accidental exposure to cyanide compounds. The core benefit is that this agent supports the body's functioning during the acute crisis.

The primary use may assist with managing profound systemic symptoms, including the mitigation of severe, critical manifestations such as circulatory instability (hemodynamic issues), severe respiratory distress, lactic acidosis, and acute neurological compromise (loss of consciousness, coma, seizures). This treatment assists with managing the acute and severe toxicity across the entire patient spectrum, including adults and the pediatric population.

“Its application is considered relevant in the context of conditions associated with acute or disruptive episodes where supportive symptom management is appropriate.”

Quick Fact: Relief for Acute Systemic Poisoning
This emergency antidote helps address symptoms related to systemic imbalance and heightened physiological activity, providing supportive relief when symptoms interfere with functional stability.

Regulatory References

  1. European Medicines Agency summary of product characteristics

Eligibility and Restrictions for Use

Cyanokit (hydroxocobalamin) is an antidote indicated for the treatment of known or suspected cyanide poisoning across all age ranges, including adults and children. Due to its use as an emergency, life-saving therapy, the official labeling lists no formal contraindications that would absolutely prohibit its use.

Populations Requiring Special Consideration

Population Eligibility Status Regulatory Context
Hypersensitivity Use caution; consider alternatives if available. Known anaphylactic reaction to hydroxocobalamin or cyanocobalamin.
Pregnancy Treatment should not be withheld. Untreated cyanide poisoning is a medical emergency that can be fatal for both the mother and fetus.
Breastfeeding Not recommended during treatment. Hydroxocobalamin and its metabolite are present in human milk.
Renal/Hepatic Impairment Use is allowed; no dose adjustment required. Administered for an acute, life-threatening emergency.

Eligibility to receive Cyanokit is primarily based on a strong clinical suspicion of cyanide poisoning, regardless of the patient’s age or pre-existing conditions. The need for immediate treatment in this emergency setting supersedes most general safety considerations.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Cyanokit (Hydroxocobalamin) is primarily characterized by physical and chemical incompatibilities with other intravenous solutions, rather than conventional pharmacokinetic or pharmacodynamic drug-drug interactions. Regulatory documents contain no specific statements regarding systemic exposure changes (AUC/Cmax), CYP enzyme interactions, or transporter-mediated interactions with co-administered medicines.

Administration Restrictions (Incompatibility)

Co-administration of Cyanokit with certain substances through the same intravenous line is prohibited due to the established risk of precipitate formation. This mandated separation applies to other cyanide antidotes, including Sodium Thiosulfate and Sodium Nitrite. Furthermore, the product is officially restricted from being mixed with various common resuscitation drugs (including Diazepam, Dopamine, Fentanyl, and Propofol), as well as Ascorbic Acid (Vitamin C). Administration alongside blood products (such as whole blood or plasma) requires a separate intravenous line, a mandatory condition to prevent incompatibility.

Procedural and Diagnostic Interference

A non-drug interaction is documented concerning the agent's deep red color, which can significantly interfere with laboratory tests for up to seven days post-treatment. This interference affects numerous colorimetric-based assays used in clinical chemistry and hematology. Additionally, the color may cause hemodialysis machines to shut down by erroneously detecting a blood leak, a known procedural constraint.

Mechanism of Action

The mechanism of action for Cyanokit's active component, hydroxocobalamin, is based on its function as a cyanide scavenger. The compound's central trivalent cobalt ion (Co^3+), coordinated within the corrin ring structure, acts as a high-affinity binding site for the cyanide ion (CN^-).

Upon intravenous administration, hydroxocobalamin rapidly distributes and penetrates intracellularly. It engages in a ligand exchange interaction; the cyanide ion is substituted for the hydroxo ligand coordinated to the cobalt center. This reaction forms cyanocobalamin, an inert and non-toxic complex.

This scavenging effect reduces the concentration of free cyanide, specifically reversing its inhibitory interaction with the biological target, cytochrome c oxidase (Complex IV) in the mitochondrial electron transport chain. By removing the allosteric inhibition of cytochrome c oxidase, the downstream intracellular pathway of oxidative phosphorylation is restored, permitting the cell to resume aerobic respiration and ATP synthesis.

System-level physiological consequences include the clearance of the stable, non-toxic cyanocobalamin complex, which is renally excreted, and the re-establishment of cellular oxygen utilization.

Dosage and Administration Information

The administration of Cyanokit (hydroxocobalamin) is strictly reserved for the emergency treatment of known or suspected cyanide poisoning and should be given without delay. It is administered as an intravenous (IV) infusion.

Preparation and Administration

To prepare the dose, the vial of lyophilized powder must be reconstituted with 200 mL of diluent, using the supplied sterile transfer spike. The recommended diluent is 0.9% Sodium Chloride injection, though Lactated Ringer's or 5% Dextrose injection may be used if the preferred diluent is unavailable. After adding the diluent, the vial must be repeatedly inverted or rocked, not shaken, for at least 60 seconds (one minute) to mix. The reconstituted solution should be dark red and must be discarded if not dark red or if particulate matter is observed.

Age Group Initial Dose Infusion Time Subsequent Dose (if needed) Maximum Total Dose
Adults 5 g Over 15 minutes 5 g 10 g
Pediatric (0–18 yrs) 70 mg/kg (Max 5 g) Over 15 minutes 70 mg/kg (Max 5 g) 140 mg/kg (Max 10 g)

The initial dose for both adults and pediatric patients is administered over 15 minutes. Depending on the patient's condition and clinical response, a subsequent dose may be given. The infusion rate for the second dose can range from 15 minutes (for patients in extremis) to 2 hours.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cyanokit

Evidence Supporting the Approved Indication (Acute Cyanide Poisoning)

Due to the life-threatening nature of acute cyanide poisoning, standard human controlled trials—where some acutely poisoned patients would receive a placebo—were ethically unfeasible for researchers to conduct. Therefore, the regulatory approval for Cyanokit was evaluated through a specialized framework established by the U.S. Food and Drug Administration (FDA) and other bodies. This framework relies on non-clinical research conducted in relevant animal models, such as lethally poisoned dogs.

In these animal studies, researchers observed survival rates over defined time intervals and observed other physiological outcomes, such as neurological and cardiopulmonary stability, during and after administration. The findings in these animal models described survival results that were submitted as part of the regulatory approval process. The primary evidence for human use is derived from these non-clinical models, reflecting the necessary reliance on animal data for efficacy. The lack of human controlled trial data remains an inherent limitation imposed by the severity and emergency nature of the condition was studied for.

Observational Data in Clinical Practice

Controlled human efficacy studies are not available; however, uncontrolled observational studies and retrospective reports exist from emergency settings. This research has explored the most common real-world setting: suspected cyanide poisoning resulting from closed-space fire smoke inhalation.

In these observational settings, studies monitored patient outcomes like survival to hospital discharge and changes in cardiovascular status. Findings describe patterns observed in these patient groups who were often critically ill. However, the evidence derived from these settings often involves confounding variables, and the evidence quality is naturally limited by the lack of a control group.

Study Design Limitations and Research Gaps

The research base for Cyanokit has specific Study Design Limitations. The primary limitation is the absence of human controlled data to definitively isolate changes in outcomes related to the use of the medicine. The quality of clinical evidence for the approved indication varies across studies, often relying on uncontrolled case series and reviews. Furthermore, long-term effects are not fully established, and while immediate survival was studied for the primary outcome, the available research provides limited insight into long-term functional or neurological outcomes following acute poisoning.

Frequently Asked Questions (FAQ)

Common questions about Cyanokit (FAQ)


Q: How quickly does Cyanokit start working after injection?

A: Regulatory information indicates that Cyanokit's active substance rapidly moves throughout the body and enters the cells to begin its action. Because it is used in a severe emergency, the clinical effect is primarily monitored by healthcare professionals, who observe the patient's overall condition and clinical response to the treatment, looking for signs that the cyanide toxicity is reversing.


Q: What is the expected duration of effect for a dose of Cyanokit?

A: Official information states that the compound formed when Cyanokit neutralizes cyanide is non-toxic and is removed from the body by the kidneys. While its therapeutic effect is immediate, signs of the drug's presence, such as red or reddish-brown discoloration of the skin and urine (chromaturia), may persist for several weeks. Red urine has been reported to last up to 35 days.


Q: What are the severe, but rare, interactions of Cyanokit with other drugs?

A: Specific drug-to-drug interactions that affect how the body processes Cyanokit have not been studied or documented in regulatory labels. However, the product is known to be physically incompatible with several other intravenous (IV) solutions, including certain other cyanide antidotes, blood products, and specific medications used during resuscitation. For this reason, official safety information mandates that Cyanokit must not be administered in the same IV line as these other substances.


Q: Is it normal to feel a burning or itching sensation at the injection site?

A: Yes, infusion site reactions are listed in official product information as common side effects. These reactions can include pain, swelling, irritation, or inflammation at the part of the body where the medicine was infused.


Q: How is the dosage of Cyanokit determined in an emergency?

A: The initial dose of Cyanokit is standardized for rapid administration in an emergency. The decision to administer a subsequent, second dose is a clinical decision made by the healthcare team based on the severity of the patient's cyanide poisoning and how well they respond to the initial treatment.


Q: Does Cyanokit help with carbon monoxide poisoning too?

A: No. Official regulatory documents clearly state that Cyanokit is indicated only for the emergency treatment of known or suspected cyanide poisoning. It is not indicated for carbon monoxide poisoning, even though cyanide and carbon monoxide exposure often occur together during smoke inhalation from a fire.


Q: How effective is Cyanokit at reversing symptoms like loss of consciousness?

A: Due to the life-threatening nature of cyanide poisoning, controlled human trials are not available. However, observational studies in emergency settings have looked at patient outcomes and have described that neurological effects, such as altered consciousness, were observed to resolve in some critically ill patients who received Cyanokit.


Q: Is Cyanokit a common drug found in ambulances or ERs?

A: Cyanokit is a critical, life-saving medication used for immediate intervention in emergency settings such as hospitals and ambulances, consistent with its indication for acute poisoning. Its use is strictly reserved for the emergency treatment of known or suspected cyanide poisoning.


Q: Does Cyanokit only treat poisoning from fire smoke?

A: No. While smoke inhalation from closed-space fires is a common source of cyanide poisoning and a frequent use case for Cyanokit, the official indication is for the treatment of known or suspected cyanide poisoning from any source. This can include inhalation, ingestion, or skin exposure to various cyanide-containing compounds.


Q: How long do the side effects from Cyanokit usually last?

A: The duration of side effects varies. For the most distinguishing effect—the red discoloration of the skin and urine—the red color in the skin may last up to 15 days, and the red color in the urine (chromaturia) may last up to 35 days. Other effects, like an acne-like rash, can appear a week or more after treatment and usually disappear within a few weeks.


Q: Are there any long-term side effects associated with Cyanokit use?

A: The drug and its non-toxic metabolite (cyanocobalamin) are known to persist in the body for several weeks, as shown by the prolonged presence of red urine. Beyond this time frame, long-term functional or neurological outcomes have not been fully established in the available research.


Q: Can a pregnant woman be treated with Cyanokit in an emergency?

A: Official labeling states that because untreated cyanide poisoning is fatal for both mother and fetus, the emergency treatment is not to be withheld from a pregnant woman.


Q: Are there different considerations for the elderly receiving Cyanokit?

A: While specific studies focusing only on older adults have not been conducted, official prescribing information advises caution. Dosage decisions for elderly patients should reflect the greater likelihood of decreased heart, kidney, or liver function, and the presence of other medical conditions or medications.


Q: What is the historical background of using this type of drug for poisoning?

A: The active substance in Cyanokit, hydroxocobalamin, is related to Vitamin B12a. This compound has been used as a vitamin supplement since the 1950s. Its use as an antidote relies on its unique chemical structure, but regulatory documents do not provide a detailed historical timeline of its initial use in poisoning.


Q: Is Cyanokit used in countries outside of the U.S.?

A: Yes. Official sources confirm that Cyanokit has been licensed and granted marketing authorization throughout the European Union. It was also licensed in France prior to the EU-wide approval, indicating its recognition and use in multiple countries outside of the United States.


Q: Can Cyanokit cause a temporary increase in heart rate?

A: Yes, an increased heart rate (tachycardia) has been observed as an adverse reaction in some patients with known or suspected cyanide poisoning who received Cyanokit. This is documented alongside the more commonly noted transient increase in blood pressure.


Q: Is there a risk of kidney issues after administration of Cyanokit?

A: Serious adverse reactions including acute renal failure (a severe type of kidney damage), renal impairment, and crystals in the urine have been reported following Cyanokit therapy. Due to these risks, official safety information recommends monitoring kidney function for up to seven days after the drug is given.


Q: Why do doctors refer to Cyanokit as a vitamin derivative?

A: Doctors and medical texts may refer to it this way because the active substance, hydroxocobalamin, is chemically related to and derived from Vitamin B12a (Aquocobalamin). It belongs to the cobalamin class of compounds.


Q: Is Cyanokit painful when administered?

A: Infusion site reactions are listed as common adverse reactions in official product information. These reactions can include pain, swelling, or irritation at the injection site.


Q: What are the physical signs that indicate Cyanokit is needed?

A: The decision to use Cyanokit is based on clinical suspicion of cyanide poisoning. Physical signs that can lead to its use include severe symptoms after exposure, such as altered mental status (confusion or unresponsiveness), seizures, coma, or hypotension (low blood pressure).


Q: Does Cyanokit contain any common allergens?

A: Official labeling warns that caution is required if a patient has a known severe allergic reaction (anaphylaxis) to hydroxocobalamin or cyanocobalamin.


Q: Can Cyanokit be administered more than once?

A: The treatment plan includes an initial dose, and regulatory information confirms that a second dose may be administered by a healthcare professional, depending on the patient’s clinical response.


Q: What is the chemical reaction that makes Cyanokit effective?

A: The effectiveness of Cyanokit is due to a rapid chemical process called a ligand exchange reaction. The active ingredient, hydroxocobalamin, acts as a cyanide scavenger by quickly trapping the toxic cyanide molecule. This reaction forms a stable, non-toxic compound called cyanocobalamin.


Q: Is Cyanokit an over-the-counter product?

A: No. According to the official product information, Cyanokit is a prescription-only drug. It is a highly specialized antidote intended only for use by trained healthcare professionals in an emergency setting.


Q: Does Cyanokit leave a residue in the body?

A: The product works by converting toxic cyanide into a non-toxic compound, cyanocobalamin, which is then safely excreted through the kidneys. A visible sign of the drug's presence, the red discoloration of the skin and urine, may persist for several weeks as the drug leaves the body.


Q: How is Cyanokit stored before use?

A: The unreconstituted vials of powder must be stored at controlled room temperature (about 25 C), and must be protected from light by remaining in their original carton. They must not be refrigerated or frozen, as this can compromise the product's stability.


How should Cyanokit be stored and disposed of?

How to Store and Dispose of Cyanokit

Proper storage and disposal of Cyanokit (hydroxocobalamin) are essential for maintaining the product's stability and safety. The unreconstituted vials should be stored at controlled room temperature, 25 C (77 F), with permitted excursions between 15 C and 30 C (59 F and 86 F).

It is crucial to store the vials in their original carton to protect the product from light. Do not refrigerate the unreconstituted vials, and protect them from freezing. The product must be kept out of reach of children.

Once the solution is reconstituted, it should be administered promptly. The stability period for the reconstituted solution is 6 hours when stored at 2 C to 25 C (36 F to 77 F). Any unused portion of the drug must be discarded following local regulations and institutional procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cyanokit found in:

A-Z Index: